Ethical Issues in Palliative Care: Considerations

Journal of Pain and Palliative Care Pharmacotherapy

Volumn 17, Issue 42067, 2004, Pages 141-149

  Manima, Abdulla ^a  

^a Pain and Palliative Care Society   (India)

Author keywords

developing world; ethics; Palliative care

Indexed keywords

ANTIRETROVIRUS AGENT; DIDANOSINE; ENFUVIRTIDE; RITONAVIR; STAVUDINE; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; CANCER PATIENT; DEVELOPING COUNTRY; DRUG COST; DRUG INDUSTRY; ETHICS; HEALTH CARE ACCESS; HEALTH CARE DELIVERY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MEDICAL ETHICS; PALLIATIVE THERAPY; REVIEW;

ANALGESICS, OPIOID; ANTI-HIV AGENTS; CONFLICT OF INTEREST; DEHUMANIZATION; DEVELOPING COUNTRIES; DRUG INDUSTRY; ETHICS, CLINICAL; HEALTH SERVICES ACCESSIBILITY; HIV INFECTIONS; HUMAN EXPERIMENTATION; HUMANS; PAIN; PALLIATIVE CARE; SOCIAL JUSTICE; WESTERN WORLD;

EID: 1542377363     PISSN: 15360288     EISSN: 15360539     Source Type: Journal    
DOI: 10.1080/J354v17n03_21     Document Type: Article

References (17)

1. Roy D J. Palliative Care Canada: A question period. J Palliat Care 1999; 15 (1) 3 – 5
2. Sathyamala Bhanot N. Nirmalasundaram How did doctors of modern medicine come to exercise complete control over all matters related to ill health?-Taking
3. Moore M. Stupid White Men. Reagan Books, Harper Collins, New York 2001
4. Mittra I. Fight against Cancer in countries with limited resources. European Journal of Cancer 1997; 33 (4) 511
5. Ferriman A. I billion dollar drug deal creates debt for tomorrow's AIDS orphans. BMJ 2000; 321: 784
6. Allan K. Health promoting palliative care, 1999. Mortality 1999; 4 (1) 75 – 82
7. Sidley P. South Africa to tighten control on drug trials after five deaths. BMJ 2000; 15 (4) 1028
8. Maria A. Investigators responsibilities for human subjects in developing countries. New Engl J Med 2000; 342: 921 – 9
9. Freemann H P, Payne R. Racial injustice in health Care. New Engl J Med 2000; 342: 1094 – 1100
10. Peay M Y, Peay E R. The role of commercial sources in the adoption of a new drug. Soc Sci Med 1988; 26: 1183
11. Avon J, Chen M, Hartley R. Science v/s commercial sources of influence on physician's behavior. Amer J Med 1982; 73: 4 – 8
12. Day R. How to make the most of a visit from a pharmaceutical company representative. Australian Prescriber 2000; 23 (5) 97
13. Bruera E, Ripamonti C, Beattie-Palmer L. Use of trade names of drugs in abstracts from pain congresses. New Engl J Med 2000; 343 (11) 818
14. Steinmann M A, Shlipak M G, McPhee S J. Of principles and pens. Attitudes and practices of medicine house staff towards pharmaceutical industry promotions. Amer J Med 2001; 110 (7) 551 – 7
15. America's largest Corporations. Fortune 500, Fortune annual special edition. 2002, Families USA: where drug dollars go?
16. Brian N. Culture, palliative care. International Journal of Palliative Nursing 2002; 18 (5) 240 – 246
17. Sternsward J, Pampallona S. Palliative medicine-A Global Perspective. Oxford text book of Palliative Medicine, G Hanks, et al. Oxford University Press, NY 1988